

FIRST HALF FINANCIAL INFORMATION AS OF 30 JUNE 2009

(NOT AUDITED)

CEGEDIM RESILIENT TO THE CRISES

AND CONFIRMS ITS TARGET OF 6% REVENUE GROWTH IN 2009

Paris, August 12, 2009 – Cegedim, the world's leading CRM (Customer Relationship Management) provider for the pharmaceutical industry, generated consolidated revenues of €434 million in the first half of 2009. This amounts to year-on-year like-for-like growth* of 4.9% and a 4.8% increase over first half 2008 on a reported basis.

€ thousands	First-half	First-half	Change H1 09 / H1 08	
	2009	2008	Reported	L-f-L*
CRM and strategic data	235,147	236,580	-0.6 %	-1.8 %
Healthcare professionals	140,762	124,795	+12.8 %	+15.4 %
Insurances and services	57,998	52,613	+10.2 %	+10.2 %
Group	433,906	413,988	+4.8 %	+4.9 %

* at constant scope and exchange rates

Despite negative currency effects, Cegedim Group managed to post growth of close to 5% due to its teams' energetic sales efforts, which translated into numerous new contracts in every Group business sector.

Good regional distribution of revenues ensures sustained growth.

Geographic breakdown of revenues by currency

%	Euro €	Pound Sterling £	Europe excl. £ and €	US Dollar \$	Row
CRM and strategic data	50 %	4 %	8 %	26 %	12 %
Healthcare professionals	79 %	21 %	0 %	0 %	0 %
Insurances and services	99 %	0 %	1 %	0 %	0 %
Group	66 %	9 %	4 %	14 %	7 %

€ thousands	Q1 2009	Q2 2009	Q1 2008	Q2 2008
CRM and strategic data	115,568	119,579	115,764	120,816
Healthcare professionals	66,137	74,625	48,684	76,111
Insurances and services	26,957	31,041	25,379	27,234
Group	208,662	225,244	189,827	224,161

CRM and strategic data

First-half 2009 revenues came to €235 million, a 1.8% like-for-like drop* and a 0.6% drop on a reported basis. Exchange rates had a positive impact on *CRM and strategic data* revenues of 0.8%.

Results in the “*Strategic data*” sector were marked by postponed orders, which hurt the performance of the *CRM and strategic data* division, but the Group expects to make up the lost ground in the second half.

By contrast, sales at the CRM business were remarkably brisk. Highlights include:

- A three-year global agreement with *Sanofi-Aventis* for the *Mobile Intelligence* solution;
- A 32-country agreement for SaaS deployment of *Mobile Intelligence* with one of the world’s leading biotech companies;
- New and promising contacts in Europe in OTC, one of the most dynamic segments of the pharmacy market;
- New contracts for *Mobile Intelligence* solutions in the USA with a division of *Bristol Myers Squibb* and for SaaS deployment to several companies, including *Auxilium Pharmaceuticals*. Furthermore, the CRM business also signed several marketing solutions and compliance contracts in the first half.

Also noteworthy was the US launch of a counterfeit pharmaceuticals monitoring activity.

Healthcare professionals

First-half 2009 revenues came to €141 million, a 15.4% like-for-like increase* and a 12.8% rise on a reported basis. Exchange rates had a negative impact on *Healthcare professionals* revenue of 2.3%, due notably to the euro’s appreciation against the British pound.

- The physician, pharmacist and paramedic software publishing business sustained its robust growth, notably in the UK.
- Cegelease (financial leases) continued to grow briskly in the first half. It should be noted that in the second quarter of 2008, the company sold a portfolio of existing lease contracts, including the contracts it signed in the first quarter of 2008, to a group of banks. As a result, second-quarter 2008 revenues were abnormally high and those of the first quarter abnormally low.

Insurances and services

First-half 2009 revenues came to €58 million, a 10.2% like-for-like increase* and a 10.2% rise on a reported basis.

- The level of activity in the computerization of insurers and mutual insurance companies, as well as in data flow management, is remarkable due notably to external growth.
- Growth accelerated in the second quarter for *Cegedim SRH*, a payroll and human resources outsourcing specialist.

Important events and transactions in H1 2009

As part of the effort to strengthen its positions in *CRM and strategic data*, on July 1, 2009 the Group acquired Group Nomi, a leading supplier of business intelligence and sales effectiveness dedicated to the pharmaceutical industry in the Nordic countries. The company has close to 200 clients, including the world's biggest pharmaceutical companies.

The businesses involved in the deal represented revenues of around SEK 60 million in 2008 and will make a positive contribution to Cegedim Group's consolidated figures in H2 2009.

Under the agreements signed by the two parties, the terms of the deal are confidential.

Financial position

Cegedim's key ratios show that its financial situation is under control. As a result, the Group is confident in its ability to respect its covenants, as of June 30, 2009 in particular, and meet its twice yearly partial debt repayments obligations of €29.5 million and \$17 million.

2009 outlook

Cegedim reiterates its 2009 revenue growth target of 6%.

Furthermore, all of the cost-cutting policies initiated in 2008 and continued 2009 are likely to have a positive impact on margins from the first half of this year onward. This impact will more than offset the slight drop in business at the *CRM and strategic data* sector.

Calendar

September 25th, 2009 after the stock market closing:

- First-half 2009 results announcement
- Release of Cegedim new finance website

September 28th, 2009:

- Analyst meeting at 10.00am – 24, rue de Penthièvre – Paris 8

From September 28th to October 9th 2009:

- Roadshows

November 13th, 2009 after the stock market closing:

- Third quarter 2009 revenues announcement

About Cegedim:

Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, pharmaceutical companies, healthcare professionals and insurance companies.

The world leader in pharmaceutical CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs more than 8,200 people in 80 countries and generated revenue of €849 million in 2008. To learn more, please visit our website: www.cegedim.com

Listed on NYSE Euronext Paris, compartment B – ISIN FR0000053506 – Reuters CGDM.PA – Bloomberg CGM

Media inquiries

Cegedim

Aude Balleydier
Media Relations
Tel. : +33 (0)1 49 09 68 81
aude.balleydier@cegedim.fr

Presse & Papiers Agency

Guillaume de Chamisso
Press Officer
Tel: + 33 (0)1 77 35 60 99
guillaume.dechamisso@pressepapiers.fr

Investor relations

Cegedim

Jan Eryk Umiastowski
Chief Investments Officer – Chief Investors Relations
Tel. : +33 (0)1 49 09 33 36
investor.relations@cegedim.fr